GSK (GSK) Competitors

Novo Nordisk A/S (NYSE:NVO) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, community ranking, valuation and media sentiment.

Does the media prefer NVO or GSK?

In the previous week, Novo Nordisk A/S had 22 more articles in the media than GSK. MarketBeat recorded 44 mentions for Novo Nordisk A/S and 22 mentions for GSK. Novo Nordisk A/S's average media sentiment score of 0.83 beat GSK's score of 0.39 indicating that Novo Nordisk A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	25 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	6 Negative mention(s)	1 Very Negative mention(s)	Positive
GSK	14 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more volatility and risk, NVO or GSK?

Novo Nordisk A/S has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500. Comparatively, GSK has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500.

Do insiders and institutionals believe in NVO or GSK?

11.5% of Novo Nordisk A/S shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by insiders. Comparatively, 10.0% of GSK shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Is NVO or GSK more profitable?

Novo Nordisk A/S has a net margin of 34.81% compared to GSK's net margin of 8.13%. Novo Nordisk A/S's return on equity of 84.68% beat GSK's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	34.81%	84.68%	26.29%
GSK	8.13%	48.59%	11.11%

Which has stronger earnings and valuation, NVO or GSK?

Novo Nordisk A/S has higher revenue and earnings than GSK. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$290.40B	1.02	$14.64B	$3.29	20.06
GSK	$31.38B	2.32	$3.29B	$1.59	22.18

Is NVO or GSK a better dividend stock?

Novo Nordisk A/S pays an annual dividend of $1.63 per share and has a dividend yield of 2.5%. GSK pays an annual dividend of $1.60 per share and has a dividend yield of 4.5%. Novo Nordisk A/S pays out 49.5% of its earnings in the form of a dividend. GSK pays out 100.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Do analysts rate NVO or GSK?

Novo Nordisk A/S presently has a consensus target price of $145.25, indicating a potential upside of 120.08%. GSK has a consensus target price of $43.25, indicating a potential upside of 22.66%. Given Novo Nordisk A/S's stronger consensus rating and higher possible upside, research analysts plainly believe Novo Nordisk A/S is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.80
GSK	0 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	3 Strong Buy rating(s)	2.60

Does the MarketBeat Community prefer NVO or GSK?

GSK received 391 more outperform votes than Novo Nordisk A/S when rated by MarketBeat users. However, 61.93% of users gave Novo Nordisk A/S an outperform vote while only 57.12% of users gave GSK an outperform vote.

Company	Underperform	Outperform
Novo Nordisk A/S	Outperform Votes 431 61.93%	Underperform Votes 265 38.07%
GSK	Outperform Votes 822 57.12%	Underperform Votes 617 42.88%

Summary

Novo Nordisk A/S beats GSK on 14 of the 21 factors compared between the two stocks.